Evidence map›Paper›PMID 42024175›Full record

ReviewCancer metastasis reviews2026

Evolving therapeutics in colorectal cancer peritoneal metastases.

Justin M Bader, Nicole Aguirre, Kurt S Schultz, Kwasi Ansere Ofori, Elizabeth Godfrey, Princy Gupta, Robert Tseng, Michael Cecchini, Raghav Sundar, Kiran Turaga

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer metastasis reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Justin M BaderDepartment of Surgery, Yale New Haven Hospital, New Haven, CT, USA. jay.bader@yale.edu.
Nicole AguirreDepartment of Surgery, Yale New Haven Hospital, New Haven, CT, USA.
Kurt S SchultzDepartment of Surgery, Yale New Haven Hospital, New Haven, CT, USA.
Kwasi Ansere OforiDepartment of Surgery, Yale New Haven Hospital, New Haven, CT, USA.
Elizabeth GodfreyDepartment of Surgery, Yale New Haven Hospital, New Haven, CT, USA.
Princy GuptaDepartment of Surgery, Yale New Haven Hospital, New Haven, CT, USA.
Robert TsengDepartment of Surgery, Yale New Haven Hospital, New Haven, CT, USA.
Michael CecchiniDepartment of Surgery, Yale New Haven Hospital, New Haven, CT, USA.
Raghav SundarDepartment of Surgery, Yale New Haven Hospital, New Haven, CT, USA.
Kiran TuragaDepartment of Surgery, Yale New Haven Hospital, New Haven, CT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer peritoneal metastases (CRC-PM) are highly aggressive and present distinct therapeutic challenges. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have emerged as potential therapeutic approaches, but their roles remain controversial following recent clinical trials. This review summarizes the evolving landscape of CRC-PM management, including diagnostic challenges, conflicting views of CRS and HIPEC, systemic therapies and new treatment approaches, overview of recent and ongoing landmark clinical trials, and discussion of variations in societal and global guideline recommendations.

Indexed as

Colorectal NeoplasmsPeritoneal NeoplasmsCombined Modality TherapyCytoreduction Surgical ProceduresHumansHyperthermic Intraperitoneal ChemotherapyClinical trialsColorectal cancerControversies in treatmentCytoreductive surgeryIntraperitoneal chemotherapyPeritoneal metastases

Identifiers

PMID42024175

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.